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Alpha-1-antitrypsin (AAT) deficiency is a common genetic disease which affects both lung and
liver. Early diagnosis can help asymptomatic patients to adjust their lifestyle choices in order
to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD). The determination of this
genetic deficiency prevalence in Madeira Island (Portugal) population is important to clarify
susceptibility and define the relevance of performing genetic tests for AAT on individuals at risk
for COPD.
Two hundred samples of unrelated individuals from Madeira Island were genotyped for the
two most common AAT deficiency alleles, PI*S and PI*Z, using Polymerase Chain Reaction-Medi-
ated Site-Directed Mutagenesis.
Our results show one of the highest frequencies for both mutations when compared to any
already studied population in the world. In fact, PI*S mutation has the highest prevalence
(18%), and PI*Z mutation (2.5%) was the third highest worldwide. The frequency of AAT defi-
ciency genotypes in Madeira (PI*ZZ, PI*SS, and PI*SZ) is estimated to be the highest in the
world: 41 per 1000.
This high prevalence of AAT deficiency on Madeira Island reveals an increased genetic
susceptibility to COPD and suggests a routine genetic testing for individuals at risk.
ª 2009 Elsevier Ltd. All rights reserved.51 291705390; fax: þ351
(H. Spı´nola).
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Alpha-1-antitrypsin (AAT) deficiency, first described in
1963, is a common genetic disease that affects lung and
liver and results from mutations on Protease Inhibitor (PI).
Alpha-1-antitrypsin in Madeira 1499locus located in the long arm of chromosome 14.1e4 AAT,
a glycoprotein, is a protease inhibitor that belongs to the
family of serpins and its prime function is the inhibition of
neutrophil elastase enzyme. Neutrophil elastase is an
important protease that has as substrate some components
of extra-cellular matrix and is associated to the action of
neutrophil. Because excessive presence of neutrophil
elastase results in the destruction of pulmonary paren-
chyma the correct expression of PI locus is essential in the
protection of lungs. AAT is expressed mainly in liver cells
(hepatocytes) and discharged to plasma where this glyco-
protein should be kept at sufficient high levels to protect
lung elastin from degradation by neutrophil elastase.5 AAT
deficiency leads to low plasma and alveolar concentration
of this protective glycoprotein, situation associated to
a progressive, severe, and life-threatening pulmonary
early-onset emphysema and chronic obstructive pulmonary
disease (COPD).6 Accumulation of abnormal alpha-1-anti-
trypsin in hepatocytes is also responsible for liver disease.7
AAT deficiency is most prevalent in European pop-
ulations but it has been also reported in almost all regions
of the world.8 AAT deficiency is under recognized and under
diagnosed but early diagnosis in the asymptomatic patient
helps modify lifestyle choices to reduce the risk of COPD,
namely eliminating smoking habits.8,9
PI*M is the normal and most common allele but more
than 100 different genetic variants of AAT locus were
described worldwide. The two most common mutations,
causing clinically relevant deficiency of the protein alpha-
1-antitrypsin, are PI*S and PI*Z.10 PI*S allele result from
a single base-pair substitution in exon III from Thymine to
Adenine (Blu264GAA/ Val GTA) that occur at 279e470
generations ago, probably in Iberian peninsula where it is
more prevalent. Pi*Z allele result also from a single base-
pair substitution in exon V from Adenine to Guanine (Glu342
GAG/ Lys AAG) that probably arose in Northern Europe at
107e135 generations ago, where presently it reaches higher
frequencies.11
PI*ZZ, PI*SZ, and PI*ZZ are considered deficiency geno-
types and PI*MS and PI*MZ carriers of the anomaly. Indi-
viduals with deficiency allele combinations have been
estimated to be 3.4 millions worldwide and carriers of the
anomaly about 116 millions, despite there are clear ethnic
differences on the prevalence of these alleles.8
PI*ZZ are at higher risk for COPD than PI*SZ subjects,
despite, in smokers, both genotypes represents high risk.12
Carriers of the defective allele PI*Z (PI*MZ) have also an
increased risk of COPD that manifest later in life and is
dependent on the multifactorial interaction of genetic,
smoking and environmental factors.8
Madeira Island (Portugal), located in the North Atlantic
Ocean, was uninhabited when the settlement process began
by the Portuguese in the 15th century. Settlers were mainly
Portuguese but included also people from Africa, brought as
slaves, and from different European proveniences (Spain,
Italy, France, and England) involved in North Atlantic
trade.13,14 Since the 18th century, Madeira Island has been
known all over the Europe as a place with good climatic
conditions to treat pulmonary disease and for a long time
many people moved to this island searching a cure for their
pulmonary injuries, same time as a prescription from
their physicians.15,16Some studies have been done in order to characterize
the Madeirean population genetic profile and they showed
that, besides the greater influence of Caucasians, sub-
Saharans also left an important genetic imprint on the
population.17e20
Despite several population studies have been done in
order to characterize S and Z mutations prevalence on
Protease Inhibitor locus, Madeira Island has never been
included. The aim of the present study on Madeira Island
population was to assess for the first time the unbiased
frequencies of PI*S and PI*Z alleles and calculate the
frequencies of individuals with deficiency allele combina-
tions and the number of carriers of both defective alleles in
order to clarify genetic susceptibility to COPD and defines
the importance on a general application of genetic tests on
citizens at risk.
Materials and methods
The samples, collected after informed consent, consisted
of 200 unrelated males with ages ranging from 18 to 23
years old whose parents and grandfathers were born and
living in Madeira Island. The main goal of this study con-
sisted in the characterization of PI*S and PI*Z allele muta-
tions prevalence in Madeira Island population and
predominance of AAT deficiency. The selection of 200
individuals allowed us to detect rare mutations (frequen-
cies lower than 0.005) with a probability of 99%.21
Genomic DNA was isolated from whole blood containing
EDTA using a phenol-chloroform procedure and frozen at
20 C until use. The two most common AAT deficiency
alleles, PI*S and PI*Z, were genotyped using PCR-MSDM
(Polymerase Chain Reaction-Mediated Site-Directed Muta-
genesis) as previously described with some modifications.22
PCR mixtures had a total volume of 50 ml, composed by
100 ng of genomic DNA, 0.2 U of Taq polymerase (FirePol),
buffer 1X (Solis BioDyne), 3.5 mM of MgCl2 (Solis BioDyne),
0.16 mM of each dNTP (Promega) and 20 pmol of each
primer described by Tazelaar and colleagues.22 To genotype
each sample for S and Z mutation, two different reactions
with the specific primers were carried out in a Biometra
thermal cycler with the following temperature cycling
conditions: initial 2 min denaturation at 94 C; 40 cycles of
20 sec at 95 C, 20 sec at 56 C, 30 sec at 72 C, and 7 min of
final extension at 72 C. We digested 5 ml of each PCR
product with 20 U of TaqaI restriction enzyme (New England
Biolabs, Beverly, MA) for 1 h and 30 min at 65 C, and 20 min
at 80 C. Digested DNA was subjected to electrophoresis in
a 4% agarose gel for 1 h and 45 min at 40 Volts.
Analysis
Allele and genotype frequencies were determined by gene
counting and respective confidence intervals through
Exploratory Software for Confidence Intervals (ESCI JSMS,
La Probe University, Melbourne, Australia) available
online.23
The expected numbers of AAT genotypes in Madeira
Island population were extrapolated through observed
genotype frequencies on the studied samples, except for
Pi*ZZ that was calculated from the HardyeWeinberg
1500 C. Spı´nola et al.equilibrium formula. We also assessed the prevalence of
each genotype in the population dividing the number of
estimated genotypes by the total population number.
Gene diversity, HardyeWeinberg equilibrium and
EwenseWatterson tests of selective neutrality were esti-
mated with Arlequin version 3.11.24 The same software was
used to perform an analysis of molecular variance (AMOVA),
based on Euclidean distances, with Madeira and other 36
worldwide populations from the literature: Portugal, Spain,
France, Italy, Belgium, Finland, Germany, Netherlands,
Norway, Latvia, Denmark, Estonia, Poland, Russia, Sweden,
Switzerland, United Kingdom, New Zealand, Japan, China,
India, Iran, Pakistan, Jordan, Saudi Arabia, Tunisia, Zaire,
Botswana, Congo, Gambia, Mali, Mozambique, Namibia,
Nigeria, South Africa, and Somalia.8,25,26 The total genetic
variation between Madeira Island and other populations,
namely mainland Portugal, was estimated and the corre-
spondent Fst values used to evaluate if there were signifi-
cant differences between them. Variance components were
tested for significance by nonparametric randomisation
tests using 10,000 permutations under the null hypothesis
of no population structure. The population genetic soft-
ware Arlequin v3.11 was employed in all the above
analyses.
Results
In the studied samples (nZ 200), 57 heterozygote MS, 8
heterozygote MZ, 6 homozygote SS, and 2 heterozygote SZ
were found. Therefore, the frequency of PI*M (non-S, non-
Z) allele was 635 (95% CI: 568e702) per 1000, PI*S allele was
180 (95% CI: 127e233) per 1000; and PI*Z was 25 (95% CI:
127e233) per 1000 (Table 1).
Based on allele frequencies, the AAT deficiency preva-
lence in Madeira Island population was 1/1600 for ZZ, 1/33
for SS and 1/100 for SZ, and the prevalence of carriers was
1/25 for MZ and 1/4 for MS. In Madeira population we may
expect around 158 (95% CI: 0e1.039) subjects with severe
AAT deficiency (ZZ). Details on the expected numbers of
ATT genotypes are shown in Table 2.
Madeira Island population was in HardyeWeinberg
equilibrium for AAT locus and its gene diversity was the
highest in the world (0.34), followed by Portugal and Spain
(0.25 and 0.22 respectively). EwenseWatterson neutrality
test revealed that AAT locus in Madeira population was not
submitted to selective pressures, similarly to the other 36
studied populations.
Analysis of molecular variance (AMOVA), plotting
Madeira with the 36 other worldwide populations from
literature, revealed that most genetic variance at AAT locus
is due to differences within each population (93%) and onlyTable 1 Observed allele frequencies and confidence
interval (CI) on Madeira Island population.
Alleles Frequency per 1000 CI 95%
PI*M (non-S; non-Z) 635 568e702
PI*S 180 127e233
PI*Z 25 3e477% of total genetic variance comes from differences among
them.
AAT allele frequencies in Madeira population had
statistically significant differences (P< 0.005) when
compared to any of the 36 world populations previously
stated, including Portugal, which did not reveal statistically
significant differences from Spain (PZ 0.23).
Discussion
The determination of AAT allelic frequencies in different
populations is crucial to estimate the number of subjects at
risk of developing the associated diseases. This information
is of much importance since AAT deficiency is under diag-
nosed all over the world. If healthcare systems knew the
real extent of deficiency alleles in the population they will
take action implementing early diagnosis mechanisms to
reach asymptomatic patients.
The present study describes for the first time the prev-
alence of the two most common AAT deficiency alleles, PI*S
and PI*Z, in Madeira Island population showing one of the
highest frequencies found worldwide for both mutations. In
fact, PI*S mutation in Madeira Island population (18%) has
the highest prevalence comparing to any world population
already studied, including Portugal (12.9%) and Spain
(10.4%) in the Iberian peninsula, the place of origin of this
mutation. Even PI*Z mutation reveals high frequencies in
Madeira Island (2.5%), similar to several Northern European
countries such as Denmark (2.26%), Estonia (2.45%), Poland
(2.45%) and Sweden (2.3%) and only lower than Latvia
(4.09%) and New Zealand (2.57%).8,25 The frequency of all
the AAT deficiency genotypes in Madeira Island population
(ZZ, SS, and SZ) was estimated as the highest in the world:
40.9 (95% CI: 14e68) per 1000.
The results obtained from this study were not expected
since they combine high prevalence for both mutations (S
and Z) that have distinct geographic distributions. Despite
the small contribution of some European countries, other
than Portugal, on the peopling of Madeira, there is none
that justifies from itself the observed prevalence of Z
mutation. The most likely explanation to this result is the
influence of the many people that arrived to the Island
since the 18th century from many places in Europe
searching for good climatic conditions to treat pulmonary
diseases. In fact, in the past two centuries many couples
and families arrived in Madeira Island searching for
a warmer climate where they could found better conditions
to treat their pulmonary injuries. Many of them, experi-
encing improvements in their health, decided to stay and
their descendants are now integrated and mixed in the
population.15,16 Based on their health condition, we
hypothesise that many of them, individuals and families,
could be AAT deficient or carriers of the mutations. Once
integrated with the Island population they may have
contributed to a higher prevalence of S and Z mutations.
The prevalence of S mutation in Madeira could also be
explained as a consequence of the known Portuguese main
contribution in the settlement, together with founder
effect and genetic drift mechanisms.
Despite the well-known sub-Saharan genetic influence
due to the contribution of slaves in the settlement of
Madeira Island, revealed through mtDNA, Y-chromosome
Table 2 Expected numbers of AAT genotypes in Madeira Island and respective confidence interval (CI).
Genotype Observed number
(nZ 200)
Madeira Island (nZ 253,426) a Prevalence
(1/x)
95% CI
Number 95% CI
MM (non-S; non-Z) 127 160,926 144,022e177,829 1.6 1.4e1.8
MS 57 72,226 56,362e88,091 4 3e5
MZ 8 10,137 3244e17,030 25 15e78
SS 6 7603 1612e13,584 33 19e157
SZ 2 2534 963e6032 100 42e263
ZZ 0 158b 0ce1039 1600 0ce244
a Data from Portuguese Statistics Institute, 2001.
b Value calculated from HardyeWeinberg Equilibrium formula (p2þ 2pqþ q2Z 1).
c We assume zero since lower limit of CI 95% ZZ genotype was a negative value.
Alpha-1-antitrypsin in Madeira 1501and HLA studies, our results didn’t reveal any evidence of
this contribution.17e20
The results obtained on this study recommend that the
Madeira Island healthcare system adopt mechanisms of
genetic testing to achieve early diagnosis on AAT defi-
ciency, especially in people with higher risks, namely
smokers and COPD patient relatives. This approach enables
the implementation of prevention measures on genetic
susceptible groups, reducing tobacco smoke, dust and
pollution from occupational or environmental exposition.
The unexpected prevalence of AAT deficiency in Madeira
Island highlights this population as an important case study
to better understand the relationship between this genetic
deficiency and the susceptibility to several diseases such as
COPD, Asthma, lung cancer, liver disease and colorectal
cancer. This high AAT deficiency prevalence can also allow
us to study and clarify the influence of genetic and envi-
ronmental factors in the development of pulmonary
diseases. Future studies on Madeira Island population
should address the association between AAT deficiency and
pulmonary diseases development or even other
pathologies.
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